Current trends for biosimilars in the Latin American market
| Autor: | Jorge Ponce-Zea, Nathalia Rodríguez-Burneo, Felipe Andrade, Diana C Checa-Jaramilloz, Diana Marcela Castillo, Esteban Ortiz-Prado, Jorge E. Vasconez, Claudio Galarza-Maldonado, Damaris P Intriago Baldeón |
|---|---|
| Rok vydání: | 2020 |
| Předmět: | |
| Zdroj: | Generics and Biosimilars Initiative Journal. 9:64-74 |
| ISSN: | 2033-6772 2033-6403 |
| DOI: | 10.5639/gabij.2020.0902.011 |
| Popis: | The number of approved biological medicines in the global pharmaceutical market has increased in recent decades. However, their high costs have also promoted the development of biosimilar medicines, following the expiry of the patent of the reference drug. Biosimilars are approved medicines of biological origin which have no statistically significant differences in terms of quality, safety and therapeutic efficacy in comparison with the reference biological. Drugs marketed as biomimics meanwhile are copies of monoclonal antibodies and fusion proteins that have not demonstrated bioequivalence to their reference biologicals. Across the world, regulations have been developed to ensure the safety and efficacy of biosimilar products, which can reduce public health expenditure and improve patient access to biological medicines. As a result, Latin America has begun to invest in the development of these drugs. The objective of this literature review is to describe the development of the biosimilar and biomimic market in Latin America. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|